<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e> is a <z:e sem="disease" ids="C1535926" disease_type="Mental or Behavioral Dysfunction" abbrv="">neurodevelopmental disorder</z:e> typically caused by mutations in <z:chebi fb="36" ids="29309">methyl</z:chebi>-CpG-binding protein 2 (MECP2) in which 26% of <z:hpo ids='HP_0011420'>deaths</z:hpo> are sudden and of unknown cause </plain></SENT>
<SENT sid="1" pm="."><plain>To explore the hypothesis that these <z:hpo ids='HP_0011420'>deaths</z:hpo> may be due to cardiac dysfunction, we characterized the electrocardiograms in 379 people with <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e> and found that 18.5% show prolongation of the corrected QT interval (QTc), an indication of a repolarization abnormality that can predispose to the development of an unstable fatal cardiac rhythm </plain></SENT>
<SENT sid="2" pm="."><plain>Male mice lacking MeCP2 function, Mecp2(Null/Y), also have prolonged QTc and show increased susceptibility to induced <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Female heterozygous null mice, Mecp2(Null/+), show an age-dependent prolongation of QTc associated with <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> and cardiac-related <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Genetic deletion of MeCP2 function in only the <z:mp ids='MP_0008912'>nervous</z:mp> system was sufficient to cause long QTc and <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>, implicating neuronally mediated changes to cardiac electrical conduction as a potential cause of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> in <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The standard therapy for prolonged QTc in <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e>, Î²-adrenergic receptor blockers, did not prevent <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> in Mecp2(Null/Y) mice </plain></SENT>
<SENT sid="6" pm="."><plain>To determine whether an alternative therapy would be more appropriate, we characterized cardiomyocytes from Mecp2(Null/Y) mice and found increased persistent <z:chebi fb="199" ids="26708">sodium</z:chebi> current, which was normalized when cells were treated with the <z:chebi fb="199" ids="26708">sodium</z:chebi> channel-blocking anti-<z:hpo ids='HP_0001250'>seizure</z:hpo> drug phenytoin </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with phenytoin reduced both QTc and sustained <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> in Mecp2(Null/Y) mice </plain></SENT>
<SENT sid="8" pm="."><plain>These results demonstrate that <z:hpo ids='HP_0001627'>cardiac abnormalities</z:hpo> in <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e> are secondary to abnormal <z:mp ids='MP_0008912'>nervous</z:mp> system control, which leads to increased persistent <z:chebi fb="199" ids="26708">sodium</z:chebi> current </plain></SENT>
<SENT sid="9" pm="."><plain>Our findings suggest that treatment in people with <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e> would be more effective if it targeted the increased persistent <z:chebi fb="199" ids="26708">sodium</z:chebi> current to prevent lethal <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
</text></document>